|
Twice-Daily Maraviroc |
Efavirenz |
Adjusted Difference (Lower Bound of 97.5% Confidence Interval) |
|
| Proportion who achieved viral loads <50 copies/mL |
65.3% |
69.3% |
–4.2 (–10.9) |
| Proportion who achieved viral loads <400 copies/mL |
70.6% |
73.1% |
–3.0 (–9.5) |
| Mean change in CD4 count (cells/mm3) from baseline |
170 |
144 |
26 (7–46)* |
| Number of patients with a new CDC category C diagnosis |
6 (1.7%) |
12 (3.3%) |
N/A |
